MAPT and Alzheimer disease: Though the predominant biomarker based model of AD postulates that markers of amyloid-β are abnormal first, followed by tau and neurodegeneration [154, 172], its most recent iteration recognizes that tau may well precede amyloid-β, with these detected by immunohistology, but not current biomarkers, due its greater sensitivity [172].